Pacira BioSciences reports Q4 2025 revenue of $196.9M, up 5%, and full-year 2026 guidance

Pacira BioSciences, Inc.

2025-FY EPS reported $0.16 revenue$726,411,000

Q4 2025 total revenue $196.9M (5% increase vs Q4 2024); EXPAREL sales $155.8M (+5%)
Full-year 2025 revenue $726.4M; GAAP net income $7.0M vs net loss of $99.6M in 2024
Repurchased 5.9M shares for $150.0M in 2025; $150M remaining authorization through Dec 2026
2026 guidance: EXPAREL net sales $600-620M, total revenue $745-770M, gross margin 77-79%
Strategic partnership with LG Chem for EXPAREL in select Asian-Pacific markets; Samit Hirawat appointed to board

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.